This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2000;284:2985-2986.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New Orleans—Quick and aggressive treatment of coronary events enjoyed preference over conservative approaches as results from late-breaking trials were announced at the American Heart Association's annual scientific sessions last month.

Attendees in New Orleans heard data suggesting that use of the statin class of cholesterol-lowering drugs immediately after a myocardial infarction (MI) or unstable angina significantly reduces recurrent cardiac events and strokes. They also learned that patients with such conditions fared better if treated immediately with platelet blockers, aspirin, or heparin, and underwent early catherization and revascularization rather than conservative treatment with only medical therapy.

MIRACL REPORTED

The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial randomized 3086 people, 65% male and 85% white, with an average age of 65 years and total cholesterol level of 270 mg/dL, into two double-blinded groups. Within 4 days after the acute event (non–Q-wave MI or unstable angina), and continuing . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?